SPTSSA
Basic information
Region (hg38): 14:34432788-34462240
Previous symbols: [ "C14orf147" ]
Links
Phenotypes
GenCC
Source:
- spastic paraplegia 90A, autosomal dominant (Strong), mode of inheritance: AD
- spastic paraplegia 90B, autosomal recessive (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Spastic paraplegia 90A, autosomal dominant; Spastic paraplegia 90B, autosomal recessive | AD/AR | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic; Neurologic | 36718090 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPTSSA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 3 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 3 | 0 | 0 |
Variants in SPTSSA
This is a list of pathogenic ClinVar variants found in the SPTSSA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
14-34435209-C-T | not specified | Uncertain significance (Mar 15, 2024) | ||
14-34435244-TGG-T | Spastic paraplegia 90B, autosomal recessive | Pathogenic (Dec 07, 2023) | ||
14-34435265-G-A | SPTSSA-related disorder • Spastic paraplegia 90A, autosomal dominant | Conflicting classifications of pathogenicity (Dec 07, 2023) | ||
14-34462156-A-C | not specified | Uncertain significance (Oct 20, 2021) | ||
14-34462156-A-T | not specified | Uncertain significance (Jan 04, 2022) | ||
14-34462198-T-C | not specified | Uncertain significance (Aug 02, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SPTSSA | protein_coding | protein_coding | ENST00000298130 | 2 | 29568 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.646 | 0.330 | 102420 | 0 | 1 | 102421 | 0.00000488 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.228 | 36 | 40.1 | 0.899 | 0.00000201 | 451 |
Missense in Polyphen | 4 | 9.3588 | 0.42741 | 122 | ||
Synonymous | -0.970 | 23 | 17.8 | 1.29 | 0.00000101 | 135 |
Loss of Function | 1.69 | 0 | 3.35 | 0.00 | 1.44e-7 | 36 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000108 | 0.0000108 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Stimulates the activity of serine palmitoyltransferase (SPT). The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2- SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16- CoA as substrates, with a slight preference for C14-CoA. {ECO:0000269|PubMed:19416851}.;
- Pathway
- Metabolism of lipids;Metabolism;ceramide <i>de novo</i> biosynthesis;Sphingolipid de novo biosynthesis;Sphingolipid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.113
Intolerance Scores
- loftool
- rvis_EVS
- -0.05
- rvis_percentile_EVS
- 49.39
Haploinsufficiency Scores
- pHI
- 0.184
- hipred
- N
- hipred_score
- 0.400
- ghis
- 0.608
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Low | Low |
Primary Immunodeficiency | Medium | Low | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sptssa
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- sphingolipid biosynthetic process;ceramide biosynthetic process
- Cellular component
- endoplasmic reticulum membrane;integral component of membrane;serine C-palmitoyltransferase complex
- Molecular function
- serine C-palmitoyltransferase activity;protein binding